Pharmacoeconomics and clinical practice guidelines. A survey of attitudes in Swedish formulary committees.

Abstract:

BACKGROUND:Swedish formulary committees are expected to influence prescribing practice by establishing and issuing drug lists and clinical practice guidelines, particularly now that financial responsibility for prescription drugs has been transferred from the national to the county council level. OBJECTIVE:The purpose of this exploratory study was to identify the information sources and decision criteria that individual committee members perceive as important in establishing clinical practice guidelines. Moreover, obstacles to the increased use of pharmacoeconomic evaluations in decision-making were also identified. DESIGN AND SETTING:Data were gathered through a survey questionnaire administered in 1998 to members of central formulary committees throughout Sweden, as determined by a national register. PARTICIPANTS:312 members of central formulary committees, of whom 69% responded. RESULTS:Treatment policies/guidelines supplied by government authorities, or found in reviewed journals, are considered the most important sources of information, and criteria associated with costs and effects are considered the most important decision criteria. The members' years of experience and their professions affect their assessments of information sources, whereas education in health economics affects their assessments of decision criteria. Committee members voiced an interest in pharmacoeconomic issues, but warned that there was neither sufficient competence among committee members nor an adequate supply of relevant studies. Furthermore, a majority of the members identified difficulty in translating study results into clinical practice guidelines and limited possibilities in comparing studies as obstacles to the increased use of pharmacoeconomic evaluations. CONCLUSIONS:The results of this survey may be useful in designing future economic evaluations and when presenting and diffusing study results.

journal_name

Pharmacoeconomics

journal_title

PharmacoEconomics

authors

Anell A,Svarvar P

doi

10.2165/00019053-200017020-00006

subject

Has Abstract

pub_date

2000-02-01 00:00:00

pages

175-85

issue

2

eissn

1170-7690

issn

1179-2027

journal_volume

17

pub_type

杂志文章
  • Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.

    abstract:INTRODUCTION:This analysis compared the cost effectiveness of adding ezetimibe to atorvastatin therapy versus atorvastatin titration or adding cholestyramine (a resin) for patients at high risk of a coronary artery disease (CAD) event who did not reach target cholesterol levels on their current atorvastatin dosage. The...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200624080-00007

    authors: Kohli M,Attard C,Lam A,Huse D,Cook J,Bourgault C,Alemao E,Yin D,Marentette M

    更新日期:2006-01-01 00:00:00

  • The Nelson Prescribing Project. A programmed intervention in general practice in New Zealand.

    abstract::We have defined the effect and acceptability of a locally developed general practice programme for the modification of prescribing. This voluntary programme consisted of prescription analysis and feedback, followed by visits from a pharmacist, a therapeutic bulletin on benzodiazepine prescribing, and use of a locally ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199507060-00009

    authors: Ferguson RI,Salmond CE,Maling TJ

    更新日期:1995-06-01 00:00:00

  • Time trends and determinants of pharmaceutical expenditure in China (1990-2009).

    abstract:BACKGROUND:Pharmaceutical policy reform is currently one of the primary areas of health reform in China. The national pharmaceutical policy of China has multiple objectives: to develop the domestic pharmaceutical industry and encourage innovation, to control escalation of total pharmaceutical expenditures (TPE) which c...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-013-0072-3

    authors: Shi L,Yang HY,Cheng G,Meng Q

    更新日期:2014-03-01 00:00:00

  • Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.

    abstract::Cefotaxime is a parenterally administered third generation cephalosporin with a broad spectrum of antimicrobial activity. After more than a decade of use, cefotaxime continues to play an important role in the treatment of patients with serious infections, particularly those caused by Gram-negative bacteria. Clinical t...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199813010-00009

    authors: Plosker GL,Foster RH,Benfield P

    更新日期:1998-01-01 00:00:00

  • The state of health economic research in South Africa: a systematic review.

    abstract:BACKGROUND:Economic factors are a limiting factor toward the implementation of many health programmes and interventions. Economic evaluation has a great potential to contribute toward cost-effective healthcare delivery in South Africa. Little is known about the characteristics and quality of health economic (including ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11589450-000000000-00000

    authors: Gavaza P,Rascati KL,Oladapo AO,Khoza S

    更新日期:2012-10-01 00:00:00

  • Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

    abstract::The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of golimumab (Schering-Plough/Centocor) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of active and progressive psoriatic arthritis (PsA) in patients who have responded inadequately to ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11595920-000000000-00000

    authors: Yang H,Craig D,Epstein D,Bojke L,Light K,Bruce IN,Sculpher M,Woolacott N

    更新日期:2012-04-01 00:00:00

  • Future of Data Analytics in the Era of the General Data Protection Regulation in Europe.

    abstract::The development of evidence to demonstrate 'value for money' is regarded as an important step in facilitating the search for the optimal allocation of limited resources and has become an essential component in healthcare decision making. Real-world evidence collected from de-identified individuals throughout the conti...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00927-1

    authors: Kolasa K,Ken Redekop W,Berler A,Zah V,Asche CV

    更新日期:2020-10-01 00:00:00

  • The indirect costs of morbidity in type II diabetic patients.

    abstract::In an attempt to obtain an appropriate estimate of the excess costs of production losses arising from morbidity in patients with diabetes, we compared the number of sick days and permanently disabled individuals in a diabetic population and the corresponding general population. These comparisons show that the rate of ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199500081-00007

    authors: Persson U

    更新日期:1995-01-01 00:00:00

  • A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.

    abstract::Darunavir boosted by low-dose ritonavir (DRV/r), at a daily dose of 600/100 mg twice a day (bid), has been shown to be superior to alternative highly active antiretroviral therapy (HAART) regimens for the management of treatment-experienced, HIV-infected adults in the phase IIb POWER trials and the phase III TITAN tri...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11587410-000000000-00000

    authors: Mauskopf J,Annemans L,Hill AM,Smets E

    更新日期:2010-01-01 00:00:00

  • Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers.

    abstract::This tutorial presents practical guidance on transforming various types of information published in journals, or available online from government and other sources, into transition probabilities for use in state-transition models, including cost-effectiveness models. Much, but not all, of the guidance has been previou...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00937-z

    authors: Gidwani R,Russell LB

    更新日期:2020-11-01 00:00:00

  • Selective versus nonselective beta adrenoceptor antagonists in hypertension.

    abstract::The application of cost-effectiveness methodology is particularly important in widespread diseases such as hypertension. However, because prospective cost-effectiveness analyses comparing different antihypertensive drugs are not currently available, differences in the cost effectiveness of these drugs can only be esti...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199508060-00006

    authors: Van Bortel LM,Ament AJ

    更新日期:1995-12-01 00:00:00

  • Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort.

    abstract:BACKGROUND AND OBJECTIVE:Accurate prediction of relevant outcomes is important for targeting therapies and to support health economic evaluations of healthcare interventions in patients with diabetes. The United Kingdom Prospective Diabetes Study (UKPDS) risk equations are some of the most frequently used risk equation...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-019-00822-4

    authors: Laxy M,Schöning VM,Kurz C,Holle R,Peters A,Meisinger C,Rathmann W,Mühlenbruch K,Kähm K

    更新日期:2019-12-01 00:00:00

  • Economic benefits of amlodipine treatment in patients with coronary artery disease.

    abstract:OBJECTIVE:To estimate the potential savings in overall cardiovascular disease (CVD) treatment costs for the US population with coronary artery disease (CAD) resulting from the use of amlodipine. STUDY DESIGN AND METHODS:Using patient-level data from a retrospective analysis of the Prospective Evaluation of the Vascula...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-200220080-00005

    authors: Casciano R,Doyle JJ,Chen J,Arikian S,Casciano J,Kugel H,Arocho R

    更新日期:2002-01-01 00:00:00

  • Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.

    abstract:BACKGROUND:Of 1 346 700 total deaths each year in the US, an estimated 440 100 are smoking related, making it the leading preventable cause of premature death in the US. Despite the health and economic benefits of smoking cessation being well documented, reimbursement coverage for smoking cessation therapies is general...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200826060-00004

    authors: Howard P,Knight C,Boler A,Baker C

    更新日期:2008-01-01 00:00:00

  • Does economic incentive matter for rational use of medicine? China's experience from the essential medicines program.

    abstract:BACKGROUND:Before the new round of healthcare reform in China, primary healthcare providers could obtain a fixed 15 % or greater mark-up of profits by prescribing and selling medicines. There were concerns that this perverse incentive was a key cause of irrational medicine use. China's new Essential Medicines Program (...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-013-0068-z

    authors: Chen M,Wang L,Chen W,Zhang L,Jiang H,Mao W

    更新日期:2014-03-01 00:00:00

  • Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.

    abstract::This study evaluated the cost utility of adding interferon-alpha 2b to conventional treatment in patients with multiple myeloma. It also provides a methodology for transforming complex quality-of-life profiles into a single index value on the conventional 0 to 1 quality-adjusted life-year scale (QALY). From 1990 to 19...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-199712010-00009

    authors: Nord E,Wisløff F,Hjorth M,Westin J

    更新日期:1997-07-01 00:00:00

  • Discounting in Economic Evaluations.

    abstract::Appropriate discounting rules in economic evaluations have received considerable attention in the literature and in national guidelines for economic evaluations. Rightfully so, as discounting can be quite influential on the outcomes of economic evaluations. The most prominent controversies regarding discounting involv...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-018-0672-z

    authors: Attema AE,Brouwer WBF,Claxton K

    更新日期:2018-07-01 00:00:00

  • Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes.

    abstract::The pharmacoeconomics of the low molecular weight heparin (LMWH) enoxaparin in the prophylaxis and treatment of venous thromboembolism have mostly been investigated in cost-effectiveness studies that estimated direct costs associated with treatment, using decision analyses and clinical outcome data from randomised con...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200220040-00002

    authors: Bergqvist D

    更新日期:2002-01-01 00:00:00

  • Cost comparisons of pharmacological strategies in open-heart surgery.

    abstract::Open-heart surgery (OHS) is performed to bypass occluded arteries, replace malfunctioning cardiac valves or correct congenital abnormalities. The average cost of OHS varies from $US25 057-$US79 795 (1997 values). The objective of this paper was to review economic studies of pharmacological strategies in open-heart sur...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200321040-00003

    authors: Reddy P,Song J

    更新日期:2003-01-01 00:00:00

  • Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data.

    abstract:BACKGROUND:Simulation models utilizing real-world data have potential to optimize treatment sequencing strategies for specific patient subpopulations, including when conducting clinical trials is not feasible. We aimed to develop a simulation model to estimate progression-free survival (PFS) and overall survival for fi...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00951-1

    authors: Degeling K,Wong HL,Koffijberg H,Jalali A,Shapiro J,Kosmider S,Wong R,Lee B,Burge M,Tie J,Yip D,Nott L,Khattak A,Lim S,Caird S,Gibbs P,IJzerman M

    更新日期:2020-11-01 00:00:00

  • Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

    abstract::Venetoclax is licensed to treat relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL). As part of the Single Technology Appraisal (STA) ID944, the National Institute for Health and Care Excellence (NICE) invited AbbVie, the manufacturer, to submit evidence on the use of venetoclax, within its licensed indic...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-017-0599-9

    authors: Mistry H,Nduka C,Connock M,Colquitt J,Mantopoulos T,Loveman E,Walewska R,Mason J

    更新日期:2018-04-01 00:00:00

  • Comparison of the cost-effectiveness of various therapies for common prostatic disorders.

    abstract::Diseases of the prostate currently represent a major health problem worldwide. As the age of the male population increases in the future, so will the number of patients suffering from these disorders and the cost for treatment increase. Currently, benign prostatic hyperplasia (BPH) and prostate cancer are common in ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199201050-00007

    authors: Amin EA,Amin M

    更新日期:1992-05-01 00:00:00

  • Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis.

    abstract::The annual cost of managing migraine totals billions of US dollars. This retrospective economic analysis of a clinical trial comparing subcutaneous dihydroergotamine mesylate (DHE) with subcutaneous sumatriptan in the treatment of acute migraine is appropriate because, although each product has been shown to be effica...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-199610010-00006

    authors: Payne K,Kozma CM,Lawrence BJ

    更新日期:1996-07-01 00:00:00

  • Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.

    abstract:BACKGROUND:Low-dose aspirin (ASA) is effective for secondary prevention of ischemic stroke but can increase the risks of hemorrhagic stroke, upper gastrointestinal bleeding (UGIB), and dyspepsia. Prophylactic administration of proton pump inhibitors (PPIs) reduces the risks of these digestive symptoms. We investigated ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-015-0289-4

    authors: Takabayashi N,Murata K,Tanaka S,Kawakami K

    更新日期:2015-10-01 00:00:00

  • Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.

    abstract::Pharmacoeconomic data may be obtained within the context of randomised clinical trials (RCTs) and from effectiveness studies in the 'real world'. The differences between the 2 types of study design have implications for the types of data that can be obtained and the interpretation of the resulting findings. Because RC...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199915050-00001

    authors: Revicki DA,Frank L

    更新日期:1999-05-01 00:00:00

  • An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.

    abstract:BACKGROUND:While drotrecogin alfa (activated) was shown to decrease absolute 28-day mortality by 6.1% in patients with severe sepsis in the Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study, no mortality benefit was observed in the subset of patients with only one organ system failure. C...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/BF03262331

    authors: Betancourt M,McKinnon PS,Massanari RM,Kanji S,Bach D,Devlin JW

    更新日期:2003-01-01 00:00:00

  • Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery.

    abstract:OBJECTIVE:The objective of this study was to assess the cost effectiveness of using epoetin-alpha (erythropoietin) to augment preoperative autologous donation (PAD) of blood prior to elective cardiac surgery. DESIGN AND SETTING:We designed a decision-analytic model incorporating the risk of receiving allogeneic blood,...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200018020-00006

    authors: Coyle D,Lee KM,Fergusson DA,Laupacis A

    更新日期:2000-08-01 00:00:00

  • A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life.

    abstract::The aim of this prospective sequential multinational (5 countries) study was to concurrently evaluate the effects of subcutaneous sumatriptan on clinical parameters, health-related quality-of-life (HRQOL) measures, workplace productivity and patient satisfaction. This report presents the HRQOL results. 582 patients (a...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2165/00019053-199700111-00005

    authors: Dahlöf C,Bouchard J,Cortelli P,Heywood J,Jansen JP,Pham S,Hirsch J,Adams J,Miller DW

    更新日期:1997-01-01 00:00:00

  • Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

    abstract::As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical and cost effectiveness of evolocumab. The appraisal assessed evolocumab as monotherapy or in combination with a statin...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-016-0472-2

    authors: Carroll C,Tappenden P,Rafia R,Hamilton J,Chambers D,Clowes M,Durrington P,Qureshi N,Wierzbicki AS

    更新日期:2016-11-16 00:00:00

  • Measuring sensitivity in pharmacoeconomic studies. Refining point sensitivity and range sensitivity by incorporating probability distributions.

    abstract:OBJECTIVE:The aim of the present study is to describe a refinement of a previously presented method, based on the concept of point sensitivity, to deal with uncertainty in economic studies. DESIGN:The original method was refined by the incorporation of probability distributions which allow a more accurate assessment o...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199916010-00004

    authors: Nuijten MJ

    更新日期:1999-07-01 00:00:00